Akebia Therapeutics Reports Positive Topline Data from VOCAL Trial Showing Vadadustat Dosed TIW Met Primary Endpoint of Non-Inferiority to ESA in Maintaining Hemoglobin

Article summary

Trial results add to robust dataset comparing vadadustat to the current standard of care, including recent 2,100+ patient VOICE trial that demonstrated a clinically meaningful safety benefit Trial results add to robust dataset comparing vadadustat to the current standard of care, including recent 2,100+ patient VOICE trial that demonstrated a clinically meaningful safety benefit